Nasdaq Initiates Delisting Process for Dyadic International
DYAI sits 30% above its 52-week low of $0.655.
Summary
Dyadic International has received a formal delisting notification from Nasdaq for failing to meet both the minimum bid price and continued listing standards, initiating a delisting process.
Key Events · Corporate Governance and Compliance · DYAI
-
Delisting Process Initiated
Nasdaq has formally initiated a process that could result in the delisting of Dyadic International's securities, effective June 18, 2026.
-
Failed Bid Price Compliance
The company failed to regain compliance with Nasdaq's minimum bid price rule ($1.00 per share) by the June 17, 2026 deadline.
-
Failed Extension Conditions
Dyadic did not meet the condition for a 180-day extension, specifically failing to achieve at least $5 million in shareholders' equity.
-
Non-Compliance with Continued Listing Standards
The company also failed to meet separate Nasdaq listing rules requiring minimum shareholders' equity, market value of listed securities, or net income.
Analysis · DYAI · Life Sciences
Dyadic International has received a formal delisting notification from Nasdaq for failing to meet both the minimum bid price and continued listing standards. This is a critical development following previous warnings and the company's negative shareholder equity, directly threatening its stock's liquidity and ability to raise capital. While a hearing request provides a temporary stay, there is no assurance of regaining compliance or avoiding delisting, which could significantly impair investor confidence and the company's operational viability. This event directly impacts the ongoing efforts to approve a reverse stock split, which was intended to address the bid price deficiency.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 39.1% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYAI was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $0.65 to $1.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.